Roselabs Finance (531324)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Reported profit growth of 63.64% suggests losses are narrowing from a small base.
• Latest quarter net loss is negligible at ₹-0 crore, close to breakeven.
• Piotroski F-Score of 5/9 indicates some modest positive financial signals.
• Sales are stable at ₹1 crore, with no reported decline.

Concerns

• P/E of 0.00 and negative latest-quarter profit mean there is no real earnings support.
• ROCE of -175.76% points to severe capital destruction in operations.
• ROE of 4.13% is below risk-free Indian fixed-income alternatives, compensating no risk.
• Missing book value, promoter holding, and debt data make transparency and valuation impossible.
• Tiny ₹1 crore sales base leaves no meaningful scale or growth runway.

AI Analysis

Looking at Roselabs Finance, my first impression is that this is not a business I can understand or value with confidence. The company has a market cap of ₹34 crore and sales of just ₹1 crore. That is a micro-cap financial services entity with essentially no earnings power. The P/E of 0.00 is not a bargain; it is a sign that earnings are absent or negligible. The latest quarter still shows a net loss of ₹-0 crore, though the reported 63.64% 'profit growth' suggests the loss may be narrowing from a small base. But a large percentage improvement on nothing is still nothing. I demand a fair return on capital. Here ROE is only 4.13%, below what a conservative Indian investor can earn from a fixed deposit, and ROCE is a deeply negative -175.76%. That tells me this business is destroying capital in its operations, not compounding it. There is no dividend, no sales growth, and no promoter holding information. I cannot even see the book value to estimate a floor. When data is missing, Graham would say invest on the basis of margin of safety; here the margin is invisible. The Piotroski F-Score of 5/9 is mediocre. It does not indicate a strong financial recovery. The stock trades near its 52-week high of ₹34.36, so Mr. Market is optimistic, but optimism is not analysis. In India, small finance-sector tickers often trade on speculation. I would rather sit on the sidelines and wait for either a much better business or a price well below a conservatively estimated intrinsic value. Until I see sustained profits, positive ROCE, and proper disclosure, Roselabs remains a pass. As Buffett says, 'The trick is not to learn to trust your gut, but to discipline yourself to ignore your gut.'

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer